Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

Metastatic prostate cancer can progress in different ways. In some men the disease advances rapidly, while other men have ...

ESPN’s Jay Harris reveals his prostate cancer diagnosis Read ahead to know about the symptoms men should never ignore and why ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

ESPN “SportsCenter” anchor Jay Harris revealed his prostate cancer diagnosis during an appearance on “Good Morning America” ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

The viral immunotherapy delivers a replication-defective herpes simplex virus thymidine kinase gene and was administered in ...

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic ...

Enlarged prostate does not cause prostate cancer, but both are common among older men. A North Texas urologist explains why ...